NDMC101

NDMC101 is a derivative of salicylanilide with anti-inflammatory activities.¹ It inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells when used at concentrations of 10 and 15 µM. NDMC101 (15 µM) decreases RANKL-induced expression of the osteoclastogenic genes Nfatc1, Acp5, Ctsk, Oscar, Itgb3, and Dcstamp in BMDMs and inhibits phosphorylation of IĸB and nuclear translocation of NF-ĸB in RANKL-stimulated RAW 264.7 cells. It reduces collagen-induced increases in the serum levels of TNF-α and IL-1β, as well as the numbers of osteoclasts and histological severity of bone erosion, cartilage damage, and synovial inflammation in joints in a mouse model of arthritis when used at a concentration of 62.5 mg/kg.

WARNING This product is not for human or veterinary use.

1. Cheng, C.P., Huang, H.S., Hsu, Y.C., et al. A Benzamide-linked Small Molecule NDMC101 Inhibits NFATc1 and NF-κB Activity: A Potential Osteoclastogenesis Inhibitor for Experimental Arthritis. J. Clin. Immunol. 32(4), 762-777 (2012).